Considerations for development of therapies for cutaneous neurofibroma
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 1, 2017
- Accepted in final form April 23, 2018
- First Published July 9, 2018.
Author Disclosures
- Sharad K. Verma, PhD,
- Vincent M. Riccardi, MD, MBA,
- Scott R. Plotkin, MD, PhD,
- Hubert Weinberg, MD,
- R. Rox Anderson, MD,
- Jaishri O. Blakeley, MD,
- Kurt Jarnagin, PhD and
- James Lee, MD, PhD
- Sharad K. Verma, PhD,
NONE
NONE
NONE
(1) Translational Genetics and Genomics, Editorial Advisory board member (non-compensated), 2016 - present.
NONE
NONE
NONE
(1) Genentech (2) Bristol-Myers-Squibb
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Comprehensive Cancer Network Stock/Stock Options, Medical Equipment & Materials: (1) GlaxoSmithKline (2008 - present) (2) Epizyme (2016 - present)
NONE
NONE
NONE
NONE
NONE
NONE
- Vincent M. Riccardi, MD, MBA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Scott R. Plotkin, MD, PhD,
NONE
NONE
Dr. Plotkin has been reimbursed by the American Academy of Neurology and the Children?s Tumor Foundation for travel for educational activities.
Journal of Neuro-oncology, editorial board, started 7/1/2014. Unpaid
NONE
NONE
NONE
Commercial entity. NFlection Therapeutics (a company focused on developing therapies for NF1)
NONE
Founder of NFlection Therapeutics (with other individuals)
NONE
NONE
Dr. Plotkin has received research support from the NIH (1R13NS084619-01, PI 2013-2014; 1 R01 CA201130-01A1; co-PI), Department of Defense (W81XWH-12-1-0155 and W81XWH-16-1-010)
NONE
Dr. Plotkin has received research support from an anonymous foundation.
Stock for commercial entity NFlection Therapeutics (not on board of directors but as founder) Non-financial disclosures: As noted above, I am involved with the company NFlection therapeutics which is involved in developing treatments for NF1-related tumors.
NONE
NONE
NONE
NONE
NONE
- Hubert Weinberg, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- R. Rox Anderson, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jaishri O. Blakeley, MD,
I served in an uncompensated role on a Scientific Advisory Board for Novartis in 2010. I served as a paid consultant for a medical advisory board for Abbvie June 2015 and as a paid consultant for Abbvie for clinical trial design for a glioblastoma quality of life study in 2016. I currently sit on the Medical Advisory Council for the Children's Tumor Foundation
NONE
Travel to a scientific conference in Novemebr 2017 during which I participated in a panel discussion about the drug selumetinib for brain tumors and plexiform neurofibromas. Travel expenses were paid for by AstraZenica.
Guest editor, Experimental Neurology, January 2018
NONE
NONE
NONE
I served as a compensated consultant to Abbvie in June 2015 for glioblastoma study design and as a paid consultant for Abbvie for clinical trial design for glioblastoma quality of life in 2016.
NONE
NONE
NONE
Glaxo Smith Kline non-salary research support for vestibular schwannoma clinical trial with lapatinib; Sanofi non-salary research support for glioma clinical trial; Lily non-salary research support for glioma clinical trial
NIH/NIBIB, R01EB009731; Co-investogator, 07/01/09- 04/30/13; Department of Defense Neurofibromatosis Clinical Trial Consortium site PI
NONE
Children's Tumor Fundation; Brain Tumor Funders Collaborative; American Society of Clinical Oncology
NONE
NONE
NONE
NONE
NONE
NONE
- Kurt Jarnagin, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
BioPharm Tech a consulting organization 2017-present -- no relationship to this work Pfizer -- 2016-2017 -- no relationship to this work Anacor Pharmaceuticals -- 2008-2016 -- no relationship to this work
NONE
NONE
NONE
NONE
Jarnagin servers as a general consultant to BioPharma industry. Those activities cover many areas, but none within the topic areas of the papers at issue here.
NONE
NONE
NONE
Anacor was purchased by Pfizer in 2016. As such Jarnagin received stock option-based compensation in 2016. No relationship to this work.
NONE
NONE
NONE
NONE
NONE
- James Lee, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
I am an employee of Dermavant Sciences
NONE
NONE
NONE
NONE
I am an employee of Dermavant Sciences
NONE
NONE
NONE
NONE
NONE
NONE
I receive stock options as an employee of Dermavant Sciences
NONE
NONE
- From the Department of Neurology (S.K.V., J.O.B.), The Johns Hopkins University School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program, Baltimore, MD; The NF Institute (V.M.R.), La Crescenta, CA; Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston; Division of Plastic Surgery (H.W.), Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Dermatology (R.R.A.), Harvard Medical School, Boston, MA; BioPharm Tech (K.J.), San Mateo, CA; and Dermavant Sciences (J.L.), Durham, NC.
- Correspondence
Dr. Verma sverma20{at}jhmi.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.